| Product Code: ETC9951836 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Shubham Padhi | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 United Kingdom (UK) Phosphodiesterase (PDE) Inhibitors Market Overview |
3.1 United Kingdom (UK) Country Macro Economic Indicators |
3.2 United Kingdom (UK) Phosphodiesterase (PDE) Inhibitors Market Revenues & Volume, 2021 & 2031F |
3.3 United Kingdom (UK) Phosphodiesterase (PDE) Inhibitors Market - Industry Life Cycle |
3.4 United Kingdom (UK) Phosphodiesterase (PDE) Inhibitors Market - Porter's Five Forces |
3.5 United Kingdom (UK) Phosphodiesterase (PDE) Inhibitors Market Revenues & Volume Share, By Types, 2021 & 2031F |
3.6 United Kingdom (UK) Phosphodiesterase (PDE) Inhibitors Market Revenues & Volume Share, By Indication, 2021 & 2031F |
3.7 United Kingdom (UK) Phosphodiesterase (PDE) Inhibitors Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.8 United Kingdom (UK) Phosphodiesterase (PDE) Inhibitors Market Revenues & Volume Share, By End User, 2021 & 2031F |
3.9 United Kingdom (UK) Phosphodiesterase (PDE) Inhibitors Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 United Kingdom (UK) Phosphodiesterase (PDE) Inhibitors Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of erectile dysfunction in the UK population |
4.2.2 Growing awareness about the benefits of phosphodiesterase (PDE) inhibitors in treating various medical conditions |
4.2.3 Rising adoption of PDE inhibitors in the UK healthcare sector |
4.3 Market Restraints |
4.3.1 Stringent regulations and approval processes for PDE inhibitors in the UK |
4.3.2 Competition from alternative treatment options for conditions that PDE inhibitors are used for |
5 United Kingdom (UK) Phosphodiesterase (PDE) Inhibitors Market Trends |
6 United Kingdom (UK) Phosphodiesterase (PDE) Inhibitors Market, By Types |
6.1 United Kingdom (UK) Phosphodiesterase (PDE) Inhibitors Market, By Types |
6.1.1 Overview and Analysis |
6.1.2 United Kingdom (UK) Phosphodiesterase (PDE) Inhibitors Market Revenues & Volume, By Types, 2021- 2031F |
6.1.3 United Kingdom (UK) Phosphodiesterase (PDE) Inhibitors Market Revenues & Volume, By Specific, 2021- 2031F |
6.1.4 United Kingdom (UK) Phosphodiesterase (PDE) Inhibitors Market Revenues & Volume, By Non-Specific, 2021- 2031F |
6.1.5 United Kingdom (UK) Phosphodiesterase (PDE) Inhibitors Market Revenues & Volume, By Others, 2021- 2031F |
6.2 United Kingdom (UK) Phosphodiesterase (PDE) Inhibitors Market, By Indication |
6.2.1 Overview and Analysis |
6.2.2 United Kingdom (UK) Phosphodiesterase (PDE) Inhibitors Market Revenues & Volume, By Congestive Heart Failure, 2021- 2031F |
6.2.3 United Kingdom (UK) Phosphodiesterase (PDE) Inhibitors Market Revenues & Volume, By Erectile Dysfunction, 2021- 2031F |
6.2.4 United Kingdom (UK) Phosphodiesterase (PDE) Inhibitors Market Revenues & Volume, By Inflammatory Airways Disease, 2021- 2031F |
6.2.5 United Kingdom (UK) Phosphodiesterase (PDE) Inhibitors Market Revenues & Volume, By Others, 2021- 2031F |
6.3 United Kingdom (UK) Phosphodiesterase (PDE) Inhibitors Market, By Route of Administration |
6.3.1 Overview and Analysis |
6.3.2 United Kingdom (UK) Phosphodiesterase (PDE) Inhibitors Market Revenues & Volume, By Oral, 2021- 2031F |
6.3.3 United Kingdom (UK) Phosphodiesterase (PDE) Inhibitors Market Revenues & Volume, By Parenteral, 2021- 2031F |
6.3.4 United Kingdom (UK) Phosphodiesterase (PDE) Inhibitors Market Revenues & Volume, By Others, 2021- 2031F |
6.4 United Kingdom (UK) Phosphodiesterase (PDE) Inhibitors Market, By End User |
6.4.1 Overview and Analysis |
6.4.2 United Kingdom (UK) Phosphodiesterase (PDE) Inhibitors Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.4.3 United Kingdom (UK) Phosphodiesterase (PDE) Inhibitors Market Revenues & Volume, By Homecare, 2021- 2031F |
6.4.4 United Kingdom (UK) Phosphodiesterase (PDE) Inhibitors Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.4.5 United Kingdom (UK) Phosphodiesterase (PDE) Inhibitors Market Revenues & Volume, By Others, 2021- 2031F |
6.5 United Kingdom (UK) Phosphodiesterase (PDE) Inhibitors Market, By Distribution Channel |
6.5.1 Overview and Analysis |
6.5.2 United Kingdom (UK) Phosphodiesterase (PDE) Inhibitors Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.5.3 United Kingdom (UK) Phosphodiesterase (PDE) Inhibitors Market Revenues & Volume, By Online Pharmacy, 2021- 2031F |
6.5.4 United Kingdom (UK) Phosphodiesterase (PDE) Inhibitors Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
7 United Kingdom (UK) Phosphodiesterase (PDE) Inhibitors Market Import-Export Trade Statistics |
7.1 United Kingdom (UK) Phosphodiesterase (PDE) Inhibitors Market Export to Major Countries |
7.2 United Kingdom (UK) Phosphodiesterase (PDE) Inhibitors Market Imports from Major Countries |
8 United Kingdom (UK) Phosphodiesterase (PDE) Inhibitors Market Key Performance Indicators |
8.1 Number of prescriptions for PDE inhibitors in the UK |
8.2 Patient satisfaction rates with PDE inhibitor treatments |
8.3 Number of clinical trials and research studies on PDE inhibitors conducted in the UK |
9 United Kingdom (UK) Phosphodiesterase (PDE) Inhibitors Market - Opportunity Assessment |
9.1 United Kingdom (UK) Phosphodiesterase (PDE) Inhibitors Market Opportunity Assessment, By Types, 2021 & 2031F |
9.2 United Kingdom (UK) Phosphodiesterase (PDE) Inhibitors Market Opportunity Assessment, By Indication, 2021 & 2031F |
9.3 United Kingdom (UK) Phosphodiesterase (PDE) Inhibitors Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.4 United Kingdom (UK) Phosphodiesterase (PDE) Inhibitors Market Opportunity Assessment, By End User, 2021 & 2031F |
9.5 United Kingdom (UK) Phosphodiesterase (PDE) Inhibitors Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 United Kingdom (UK) Phosphodiesterase (PDE) Inhibitors Market - Competitive Landscape |
10.1 United Kingdom (UK) Phosphodiesterase (PDE) Inhibitors Market Revenue Share, By Companies, 2024 |
10.2 United Kingdom (UK) Phosphodiesterase (PDE) Inhibitors Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here